MedTrace Logo

IM and IV SPL026 Drug Product in Healthy Participants

NCT05644093 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-03-22

No results posted yet for this study

Summary

The goal of this clinical trial is to test SPL026 given via injection into a muscle in healthy volunteers.

Conditions

Interventions

DRUG

SPL026 IV

IV dosing

DRUG

SPL026 IM

IM dosing

Sponsors & Collaborators

  • Small Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Adeep Puri, MD · HMR

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-03
Primary Completion
2023-04-05
Completion
2023-04-05

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05644093 on ClinicalTrials.gov